cover
Contact Name
Yolanda Handayani
Contact Email
yola.aksel@gmail.com
Phone
+6282157048069
Journal Mail Official
respirologyscience@gmail.com
Editorial Address
Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Location
Kota adm. jakarta timur,
Dki jakarta
INDONESIA
Respiratory Science
ISSN : -     EISSN : 24741306     DOI : https://doi.org/10.36497/respirsci.v1i3.17
Core Subject : Health,
Focuses on original article reviews and case reports in pulmonary and critical care medicine Scope: 1. Asthma 2. Chronic Obstructive Pulmonary Disease (COPD) 3. Lung Physiology and Sleep-Related Disorder 4. Lung Infection 5. Thoracic Oncology 6. Interstitial Lung Disease 7. Environmental Lung Disease 8. Tobacco Control 9. Occupational Pulmonary Disease 10. Pulmonary Intervention and Emergency Medicine 11. Respiratory critical care 12. Respiratory immunology and biomolecular
Articles 6 Documents
Search results for , issue "Vol. 1 No. 3 (2021): Respiratory Science" : 6 Documents clear
Remdesivir for COVID-19 in Indonesia : A Case Series Gembong Satria Mahardhika; Theodore Dharma Tedjamartrono; Haidar Zain; Efriadi Ismail
Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i3.22

Abstract

To date, COVID-19 still gives rise to a high mortality rate in Indonesia. The definitive therapy has yet to be found. However, some medications are said to be potential in subduing the infection, e.g. remdesivir. United States, Japan, and some countries in Europe had use remdesivir against severe COVID-19 infection. In Indonesia, no study has shown to discuss remdesivir therapy for severe COVID-19. This case series shows the first five remdesivir usages in severe COVID-19 patients in RSDC Wisma Atlet Kemayoran, Jakarta. In this retrospective case series, we include the first five severe COVID-19 patients that got remdesivir plus standard therapy in Rumah Sakit Darurat COVID-19 Wisma Atlet Kemayoran, Jakarta in October 2020. Five patients who got remdesivir in this case series experienced clinical and laboratory improvement. The ventilation and oxygenation status, as well as PF ratio and the neutrophils-lymphocytes ratio (NLR), got better. The possible side effect of remdesivir usage, renal function impairment, was not seen in these patients. At last, the five patients were discharged home with negative swab results, three until seven days after remdesivir therapy finished. Remdesivir therapy for COVID-19 in this case series is associated with a good outcome. Compassionate use of remdesivir should be considered in severe COVID-19. However, a bigger sample of randomized control trial needs to be done to show the effectiveness of remdesivir against COVID-19.
Accuracy Between CURB-65 Score and PSI in Determining The Prognosis of Community-Acquired Pneumonia Patients at H. Adam Malik General Hospital, Medan Fransisco Sentosa Pakpahan; Syamsul Bihar; Fajrinur Syarani; Putri Chairani Eyanoer
Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i3.25

Abstract

Background: Community-Acquired Pneumonia (CAP) is an important problem associated with morbidity and mortality. An accurate initial assessment is required before starting management of a CAP patient to determine the prognosis of the patient as early as possible. The CURB-65 score and PSI (Pneumonia Severity Index) are initial assessment scores that can be used. This study aimed to compare the accuracy between the CURB-65 score and the PSI in determining the prognosis in CAP patients at H. Adam Malik General Hospital Medan. Method: A descriptive study was conducted on 76 patients diagnosed with CAP. Each patient was assessed for their CURB-65 score, PSI class and mortality within 30 days of admission. Data were collected through patient medical records diagnosed CAP in 2018 and performed statistical analysis using 2x2 tables. Results: The CURB-65 ≥3 score showed accuracy (71.0%), sensitivity (53.8%), and specificity (89,2%). The CURB-65 ≥ 2 score showed accuracy (75.0%), sensitivity (82.1%), and specificity (67.6%).  Meanwhile, the Class IV-V PSI showed accuracy (77.6%), sensitivity (87.2%) and specificity (67.6%). Conclusion: The accuracy of the PSI is higher when compared to the CURB-65 score in determining the prognosis of CAP patients at H. Adam Malik General Hospital Medan. Although PSI is more accurate, CURB-65 is simpler, easier and less expensive to use
Role of Mesenchymal Stem Cells In Chronic Obstructive Lung Disease Fatmi Andari; Triya Damayanti
Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i3.26

Abstract

Therapy for Chronic Obstructive Pulmonary Disease (COPD) is currently still not giving effect to tissue repair and regeneration. Chronic Obstructive Pulmonary Disease is still a progressive degenerative disease. Stem cells through their regenerative ability offer a new promising alternative therapy for the management of degenerative diseases including COPD. There have been many studies conducted to determine the safety and efficacy of stem cells in COPD. Published research about stem cells on COPD is still in phase II. Further research is needed on a larger scale before stem cells can be widely applied in the management of COPD. Stem cells are a very promising alternative therapy and are a big leap in the medical world for degenerative diseases including COPD.
Implementation Of Clinical Pathway For Management Of Copd Exacerbation Alvin Kosasih
Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i3.21

Abstract

Background: The effectiveness for reducing the length of stay and produce better outcomes has been applied with the use of the clinical pathway. In this study, we observe the implementation of clinical pathways (CP) and evaluate their effectiveness in the management of Chronic Obstructive Pulmonary Diseases (COPD) exacerbation in Goenawan Partowidigdo Pulmonary Hospital (RSPG) Cisarua Bogor.  Method: This research is a quantitative study with an analytical survey method and cross-sectional design. Data collection was carried out by studying documentation on 304 medical record files from early 2019 to July 2020 and clinical pathway forms. Results: There were differences in clinical outcomes before and after the implementation of CP. The difference in the overall mean length of stay (LOS) using CP were 4 days while the who did not use CP were 6 days. For In-Hospital Mortality (IHM) there was 1 death in the CP group, and there were no deaths in non-CP groups. As for the Readmission Rate (RR), the results of the study showed that the most RR was in the CP group, which were 6 patients (54.5%) in 1st wards, 5 patients (62.5 %) in 2nd wards and 39 patients (70.9%) in 3rd wards. These RR results showed that CP of COPD exacerbation must be evaluated further. The average total hospital rate showed a significant difference between the two clinical methods.  The hospital rate variable had a very significant difference between the CP and non-CP methods, with a significant value of = 0.0001. Conclusion: The application of CP can reduce the length of stay (LOS) and the average total hospital rate of patients who are hospitalized for COPD exacerbation.  This CP must be evaluated further to reduce the readmission.
Programmed Death Ligand 1 (PD-L1) Expression in Lung Adenocarcinoma Patients Rahmat Hidayat; Noni Novisari Soeroso; Elisna Syahruddin; Dian Cahyadi; Setiaputra Setiaputra
Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i3.16

Abstract

Background: Programmed Death Ligand 1 (PD-L1) is a protein found in tumor cells that could inactivate T-cells. This research was done to identify the characteristics of lung adenocarcinoma patients to PD-L1 expression in Medan.  Method: Descriptive research with a cross-sectional design was used and the study was done for 12 months (January – December 2018). Sample’s collection was done at RSUP (Central Public Hospital) H. Adam Malik and the samples diagnosed with lung adenocarcinoma based on histopathological subtyping were sent to the laboratory of Dharmais Jakarta Hospital where the Ventana 22C3 Immunohistochemistry Staining was done. Results: Staining was done in 52 samples at Dharmais Jakarta Hospital and only 35 samples were deemed acceptable. In this study, participants’ ages ranged from 40 to 60 years, where the majority were male patients, 31 (88.6%) and 33 patients (82.5%) were at an advanced stage (III and IV). Conclusion: The study found that the PD-L1 expression was mostly observed in male at the age range of 40 – 60 years and stage IV lung adenocarcinoma patients with Tumour Proportion Score (TPS) of 1 – 49%.
Pneumocystis Pneumonia in Covid-19 Outbreak :A Case Report It's not all about Covid-19 Julisman Hasiholan Situmorang; Ginanjar Arum Desianti
Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i3.17

Abstract

One of the phenomena during the current Covid-19 pandemic is Early Detection of In-Patient Deterioration by public health services, especially general hospitals for early detection patients who admit with respiratory tract infections (RTIs) symptoms. However, there is a risk of misdiagnosis in differential diagnoses. Pneumocytis Carinii Pneumonia (PCP) is an opportunistic infection that can occur in immunocompromised patients. Symptoms that often appear are similar to Covid-19, such as fever, cough, runny nose, dyspnoea, diarrhea or others. It makes some difficulties for early diagnosing PCP infection during Covid-19 pandemic, whereas if it is not early treated it is could be a fatal case. Thus, during Covid-19 pandemic, it is necessary to consider other differential diagnoses in patients with RTIs symptoms or respiratory distress. It can be supported if other characteristic signs are found during clinical examination, especially if the nasopharyngeal and oropharyngeal swab results are negative.

Page 1 of 1 | Total Record : 6